F1000Research F1000Research 2046-1402 F1000 Research Limited London, UK 10.12688/f1000research.131508.2 Research Article Articles In silico drug repurposing using molecular docking and dynamics to target the protein interaction between the SARS-CoV-2 S-glycoprotein and the ACE2 receptor

[version 2; peer review: 1 approved, 2 approved with reservations]

 Hussein Dania Conceptualization Data Curation Formal Analysis Investigation Methodology Project Administration Resources Software Supervision Validation Visualization Writing – Original Draft Preparation Writing – Review & Editing https://orcid.org/0000-0002-9582-3645 a 1 Almatrafi Abdullah Data Curation Formal Analysis Investigation Validation Writing – Review & Editing 1 Gomaa Mohammed Data Curation Formal Analysis Investigation Methodology Supervision Validation Visualization Writing – Original Draft Preparation Writing – Review & Editing https://orcid.org/0000-0003-2112-9092 2 Alhowsawi AlAnood Formal Analysis Investigation Validation Visualization Writing – Original Draft Preparation Writing – Review & Editing 1 Almustafa Sarah Investigation Writing – Original Draft Preparation Writing – Review & Editing 3 Alsaihaty Hadi Investigation Writing – Original Draft Preparation Writing – Review & Editing 3 Alghamdi Manar Investigation Writing – Original Draft Preparation Writing – Review & Editing 3 Pharmacology and Toxicology, Imam Abdulrahman bin Faisal University, Khobar, Saudi Arabia Pharmaceutical Chemistry, Imam Abdulrahman bin Faisal University, Khobar, Saudi Arabia Imam Abdulrahman bin Faisal University, Khobar, Saudi Arabia dahussein@iau.edu.sa

No competing interests were disclosed.

 26 7 2024 2023 12 1452 17 7 2024 Copyright: © 2024 Hussein D et al. 2024 This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background: The protein interaction between the viral surface S-glycoprotein and the host angiotensin converting enzyme-2 receptor (ACE2) is key to the virulent nature of SARS-CoV-2. The potential role that effective drug repurposing strategies may have to help stem the impact of future outbreaks has been brought to light in the recent COVID-19 pandemic. This study outlines a comprehensive approach towards in-silico drug discovery which aims to identify hit agents that can be suitably translated into a clinical setting.

Methods: We use two different computational platforms to analyze the viral S-glycoprotein in its bound conformational state to the ACE2 receptor. We employed a comprehensive screening approach to shortlist compounds capable of binding to the viral target interface and corroborated these findings using both Schrödinger’s Glide and AutoDock Vina. Molecular dynamic simulation studies further verified the stability of the interaction at the viral-host protein interface.

Results: Lymecycline, pentagalloylglucose, polydatin, and hexoprenaline were identified as prime candidates for further studies given the robust and stable nature of their interaction at the viral-host interface and relevance for clinical testing. These agents were shown in a 100-nanosecond simulation trajectory to favorably disrupt key binding interactions at the viral-host interface and may potentially inhibit viral entry into host cells. In all hit molecules it was observed that inhibiting the interaction with the following key viral binding residues: Lys17, Gly496, Tyr 505, and key host residues: His34, Asp38, Lys353, played a critical role toward the inhibition of the viral-host protein interaction.

Conclusions: Our study is unique in its comprehensive approach to identify agents that can bind to the S-glycoprotein-ACE2 interface using multiple computational platforms. Among the hit compounds shortlisted in this study, both lymecycline and hexoprenaline may be considered as candidates for preliminarily clinical studies to assess their therapeutic potential in the management of COVID-19 infections.

 protein interaction Sars-CoV-2 S-glycoprotein Angiotensin converting enzyme-2 molecular dynamics drug repurposing. The author(s) declared that no grants were involved in supporting this work. Amendments from Version 1

The following revisions were made to the original manuscript:  1) Additional data regarding the MM/GBSA free binding energy calculations for the hit ligands has now been included in the manuscript (Table 3). 2) Additional data regarding the pharmacokinetic and toxicity profiles of the hit ligands has now been included in the manuscript (Table 4).  3) To support validation of our findings and the employed study design, additional data has been included drawing on previous experimental findings that help validate the feasibility of our docking study (available in extended data). Furthermore, new text was added highlighting the robust study design employed utilizing two different docking platforms to cross validate and verify the findings of this study. 4) A subsection addressing data availability and accessibility has been included in the Methods section. 5) The manuscript text has been updated accordingly to highlight the clinical feasibility and translatability of our hit ligands while emphasizing the benefit of employing a drug-repurposing strategy. Additional text has been included in the discussion. 6) The abstract and conclusion sections in the manuscript have been updated.

 Introduction

The novel corona virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had an unprecedented impact worldwide. It is the viral entity responsible for the Coronavirus disease 2019 (COVID-19) pandemic, which has reaped significant detrimental effects upon societies and economies worldwide. Up until present day, efforts remain ongoing towards effective infection management and control. 1

The SARS-CoV-2 virus is an enveloped single stranded RNA virus. 2 The entire viral genome has been sequenced and found to comprise of 29,881 bp encoding 9860 amino acids (GenBank no. MN908947). 2 The viral RNA codes for both structural and non-structural proteins, most notable of which are the structural S-glycoproteins or ‘spike proteins’- key to viral-host attachment and infection. 2 The S-glycoproteins are responsible for binding to the angiotensin converting enzyme 2 (ACE2) host cell receptor and initiating viral entry into the host cell. 3 Both SARS-CoV and SARS-CoV-2 bind to the host ACE2 receptor to trigger viral entry and infection, however the binding affinity of the SARS-CoV-2 S-glycoprotein to ACE2 is shown to be over 20 times greater than that of SARS-CoV S-glycoprotein and ACE2 binding interaction. 2 , 4

The viral S-glycoprotein is a trimeric protein with a characteristic ‘stalk and halo’ like appearance. 2 Its peptide chain, composed of a total of 1237 amino acids, includes the S1 (aa residues 14–685) and S2 subunits (aa residues 686–1273), which have been characterized and found to be critical for viral attachment and membrane fusion. 5 , 6 In these regions, both the critical receptor binding domain (aa residues 319–541), as well as the fusion peptide domain (aa residues 788–806), have been identified and characterized. 4 , 7

While vaccination efforts have greatly stemmed the spread of the infection, the main drawback of long-lasting vaccine efficacy appears to be the growing incidence of variants. 8 Managing the disease with currently available and approved therapeutics, remains an essential approach for treatment. However, there appears to be is no consensus on effective management strategies as of yet. 9 , 10 Drug repurposing is an attractive approach to identify novel indications and uses for approved medications. In the era of COVID-19, drug repurposing has been shown to be an essential path towards identifying potentially effective therapies for disease management. 11 , 12 An efficient strategy towards this includes employing in silico drug discovery tools and virtual screening, which has been proven to be most valuable in identifying drugs that can be repurposed towards a novel target. 11 , 13 Utilizing computational modelling platforms to visualize and identify ligand-target interactions is a powerful and efficient approach towards successful drug development. 14

This study aims to apply a comprehensive virtual screening approach using multiple platforms to identify drugs and natural products that may potentially be repurposed to inhibit the binding interaction between the SARS-CoV-2 S-glycoprotein and the host ACE2 receptor. Furthermore, the interaction profile of all hit compounds is verified by molecular dynamic simulation studies to provide a detailed insight towards the stability and nature of the binding interaction at the viral-host interface.

 Methods Materials and Software

The molecular modelling software Maestro by Schrödinger 15 and AutoDock Vina, 16 were both used for virtual screening and molecular dynamics simulation studies. The desktop workstation was equipped with Intel® Core™ i7-10700F Processor, Linux Ubuntu 22.10 operating system and a RTX 5000 graphics card.

 Crystal structures

The protein crystal structures were retrieved from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) (RRID:SCR_012820). For virtual screening and molecular dynamic simulations, the structure of the SARS-CoV-2 S-glycoprotein receptor binding domain (S-RBD) bound to the ACE2 receptor interface was used (PDB code: 6M0J).

 Virtual databases

A ligand library was compiled comprised of Food and Drug Administration (FDA) approved and worldwide approved drugs as well as approved nutraceuticals and natural compounds with verified in vivo efficacy. A total of 1100 FDA approved drugs were retrieved in SDF format from DrugBank database (RRID:SCR_002700), 17 along with a library of 3440 worldwide approved medications and 74 approved nutraceuticals. Furthermore, 1537 natural compounds with verified physiological effects in vivo, were retrieved from Zinc database (RRID:SCR_006082). 18 Table 1 summarizes the ligand categories of the compiled virtual library.

Virtual screening library of compounds derived from Drug bank and Zinc online databases.
Library Number of Compounds Database Description
Natural products with experimentally verified in vivo activity 1,537 Zinc SDF files of approved natural products with in vivo efficacy
FDA approved medications 1,100 DrugBank SDF files of FDA approved drugs
FDA approved medications 1,614 Zinc SDF files of FDA approved drugs
Worldwide (not FDA) approved medications 3,440 DrugBank SDF files of worldwide approved drugs non-FDA
Worldwide (not FDA) approved medications 4,288 Zinc SDF files of FDA approved drugs
Nutraceuticals 74 DrugBank SDF files of approved nutraceuticals
Final Comprehensive library compiled composed of all compounds listed above, redundant or repeated structures were excluded 7,476 DrugBank and Zinc SDF files of all FDA and worldwide approved medications and natural products in addition to natural products with verified physiological activity
Maestro

Protein preparation

All crystal structures were prepared using the Schrödinger Maestro’s (RRID:SCR_016748) protein preparation wizard tool. Structure preparation and minimization was done at a pH of 7.4 with corrected ionization states, polar hydrogens were added, and non-essential water molecules were removed. The entire structure was minimized and optimized with the OPLS3 force field and the default value for the RMSD of 0.30 Å was used for non-hydrogen atoms.

Ligand library preparation

Downloaded SDF structures were prepared for docking studies using the maestro Ligprep tool (RRID:SCR_016748). Structures were converted into 3D maestro format, and ionization states and chirality were optimized at physiological pH (7.4) using OPLS3 force field. The final 3D conformations were utilized for virtual screening.

Binding pocket determination and docking studies

In Schrödinger’s Maestro (RRID:SCR_016748) the binding pocket was identified using Schrödinger’s Sitemap, a single binding pocket between the interface of the RBD and ACE2 binding region (PBD 6M0J) was used. The selected binding pockets were verified by ensuring the presence of essential binding residues identified in previous studies. 6 The site score value was within the range of 1-1.1 for each of the binding pockets indicating high accessibility and druggability of the selected binding pocket. The selected binding pockets were used to generate a docking grid using Maestro’s Glide module for docking studies. The receptor grids were generated using the prepared proteins, with the docking grids centered on the identified receptor binding pocket for each protein. A receptor grid was generated using a 1.00 van der Waals (vdw) radius scaling factor and 0.25 partial charge cut-off. The binding sites were enclosed in a grid box of 20 Å 3 without constraints using default parameters. Docking was repeated and verified using three screening settings. All compounds were screened under a high-throughput docking setting and the top 200 compounds with the highest binding scores where then selected for standard precision docking, of these verified hits the top 80 compounds where further verified using extra precision (XP) docking settings. The ligands were docked using the extra precision mode (XP) without using any constraints and a 0.80 van der Waals (vdw) radius scaling factor and 0.15 partial charge cut-off. Induced fit docking was carried out with flexibility of the residues of the pocket in close proximity to the ligand.

GlideScore implemented in Glide (RRID:SCR_016748), was used to estimate binding affinity and rank ligands. The XP Pose Rank was used to select the best-docked pose for each ligand. The final list of thrice verified compounds was then analysed in detail based on binding scores and a detailed study of all binding interactions.

Molecular dynamics simulation studies

Molecular dynamic (MD) simulation studies were carried out using the Desmond Module on Schrödinger’s Maestro platform (RRID:SCR_016748). The protein preparation wizard was used to minimize the hit protein-ligand complex and the simulation environment was built using the system builder application of Desmond. A water based solvent system: TIP3P was employed to generate the simulation environment contained within an orthorhombic simulation box with 10 Å buffer parameter from the protein surface. The system was neutralized and isotonic conditions attained via the addition of counter ions and 0.15 M NaCl. All MD simulations were conducted at a temperature of 300 K and a pressure of 1.013 bar. A simulation period of 100 nanoseconds was run for each of the hit ligand-protein complexes. Analysis calculations were subsequently run and results presented using the simulation interaction diagram tool of Desmond.

Binding free energy calculations MM/GBSA

Binding free energy; molecular mechanics generalized Born surface area (MM/GBSA) was calculated using the PRIME module in Maestro (RRID:SCR_016748). MM/GBSA quantifies the difference in binding free energy calculated between the stabilized complex and individual ligand and receptor conformation. 19 The final complex configuration from compiled trajectories of a 100 ns MD simulation was used to calculate MMGBSA free energy, calculations were preformed using the OPLS_2005 force field and VSGB 2.0 solvation model. 20

Autodock vina

Docking calculations were carried out using the AutoDock vina software version 1.1.2 (RRID:SCR_011958). 16 All hydrogens were added to the ligand PDB file and Gasteiger charges were computed and all the torsion angles of the ligand were defined using the autodock-tools program. A grid box generated with the following dimensions: 36×24×-4 Å, with a grid spacing of 1 Å was used. The Lamarckian genetic algorithm was used as a search method with a total of 30 runs (maximum of 20 000 000 energy evaluations; 27 000 generations; initial populations of 150 conformers). The binding affinity calculation in AutoDock vina together with analysis of binding interactions were used to select hits for molecular dynamic simulation studies.

In-silico pharmacokinetic calculations

The Absorption, Distribution, Metabolism, and Excretion–Toxicity (ADMET) properties of the top seven hit drugs and nutraceuticals were derived and calculated from the PubChem database 21 and using SwissADME 22 and ADMETlab2.0 23 respectively.

Data availability

The crystal structures analysed during the current study are available in the PDB database, [PDB ID: 6M0J]. The molecular structures of the compound’s datasets used were obtained from DrugBank database ( https://go.drugbank.com/drugs) and Zinc database ( https://zinc.docking.org/substances/subsets/fda/).

 Results Docking studies

Upon designing the study and to this date there are no known solved crystal structures for the SARS-Cov-2 RBD and ACE2 complex bound to a ligand within the interacting binding pocket, as of such for the purpose of validation two different docking platforms were employed in the initial docking investigations to screen and shortlist suitable candidates targeting our region of interest in the viral-host interface. The Site Score tool on Maestro was used to identify the region with the highest druggability. A score of 1.1 for the region of interest identified revealed high druggability and accessibility of this binding pocket and most importantly was selected to encompasses the viral-host interactions of interest. The key interactions between the viral host and receptor have been determine and verified in previous studies ( Table 5). Validation drawn from prior experimental evidence revealed a consistent pattern associating good docking scores with experimental compounds that have been shown to interrupt the SARS-Cov-2 RBD and ACE2 interaction, complementing the findings of our study and supporting this approach of identifying agents capable of disrupting key viral-host interactions (see extended data).

Preliminary docking studies to identify ligands that interact favourably with the receptor binding domain of the spike protein, involved screening a total of over 7000 approved medications and natural compounds (see Table 1). Initial docking studies were carried out on the S-RBD and ACE2 interface using Schrödinger Glide and Autodock Vina to identify hits that would disrupt crucial protein-protein interactions. The results from both programs were analysed and compared. The compounds that showed the most favourable binding profiles and the best binding scores were shortlisted in Table 1. 34 , 35

A total of 13 were identified that consistently showed good binding scores and binding poses. The compounds shortlisted bound to the protein-protein interface, and established interactions with key residues namely, His34, Asp38, and Lys353 from the ACE-2 binding region and Lys417, Gly496 and Tyr505 from the S-RBD. Hexoprenaline and tricocin, being highly flexible molecules and n-acetylglucosamine being a relatively small molecule were able to burrow deeply within the protein interface, while maintaining interactions with the above-mentioned key residues ( Figure 1). The hit compounds all expressed high binding affinity scores using both platforms; ranging from -7.5 to -12.4 (Glide scoring), and -4.8 to -8.9 (Autodock vina scoring).

Surface representation of the 13 hits bound to the ACE-2 S-glycoprotein interface.

ACE-2 residues with carbon in green and S-glycoprotein residues with carbon in brown. The hit compounds are represented in yellow with hexoprenaline, n-acetyglucosamine, and tricocin highlighted in magenta.

Lymecycline, as an example, established key interactions via its side chain groups ( Figure 2). The carboxylate group formed a crossbridge at the interface; with strong charge assisted H bonds shown between the Asp38 and Lys353 sidechains from ACE-2 and the Gly496 sidechain from the spike protein. The interaction was further strengthened by the ammonium ion of the terminal amino acid forming a charge assisted H bond with both the His34 backbone (ACE2) and Gly496 sidechain (S-RBD). A water mediated H bond for this ammonium ion with the Tyr453 sidechain of the S-RBD was also observed. Potential H bonds were also noted between the sidechain amide oxygen and Lys417, as well as the ring’s tertiary amine with Tyr505 from the spike protein. An increase of selectivity for lymecycline is expected owing to the presence of two opposite electrostatic interactions with both chains; the first being a H bond between the sidechain amide and His34 sidechain (ACE-2), and the second a H-π interaction between the central aliphatic ammonium and Tyr453 aromatic ring (S-RBD).

Binding interactions of lymecycline with the ACE-2 S-glycoprotein interface.

ACE-2 residues with carbon in green and S-glycoprotein residues with carbon in brown. Potential electrostatic interactions are represented as red dotted lines and distances are in Angstrom.

 MD simulation results

The top hit molecules were selected based on a detailed visual analysis of the interaction profile of each compound with the target proteins. A hit was identified as any compound which had a favourable binding score and profile. Compounds were shortlisted based on reproducibility of the results using two different docking platforms (Glide and AutoDock Vina). A total of 13 hit ligands were selected for molecular dynamic simulation studies ( Table 2). Investigation of the optimal 2D and 3D docked positions revealed that each of the hit ligands form interactions with key residues of the binding pocket. Root mean square deviation (RMSD) plot analysis was used to measure the average displacement of atoms with respect to a reference frame. RMDS analysis revealed a stable binding profile for the top 7 ligands as shown in Figure 3 (RMSD fluctuation range of 2-4 Å). Of the 7 hit ligands, 3 exhibited a highly stable and robust binding profile within the interface binding pocket, these include: lymecycline, pentagalloylglucose and polydatin. The interaction profile for each individual ligand is depicted in Figures 4- 6 (for MD results for the remaining 4 ligands see extended data). As the S-RBD-ACE2 interface structure was used for simulations, all interactions of the ligand with key binding residues of both chain A of the ACE2 binding domain and chain E of the S-RBD were considered as significant.

The individual docking scores for the hit molecules using both AutoDock Vina and Schrödinger’s Glide at the interface of the S-glycoprotein and ACE2 receptor PDB 6M0J.
Ligand Binding affinity (kcal/mol) Software: Schrödinger Glide Binding affinity (kcal/mol) Software: AutoDock Vina
Colistin -12.4 -4.8
Argipressin (vasopressin) -9.7 -6.8
Lymecycline -9.1 -8.3
Setmelanotide -9.0 -6.1
Polydatin -7.6 -8.5
Plazomicin -10.6 -7.3
Hexoprenaline -10.1 -6.5
Tricrocin -9.1 -8.4
Ginsenosides -11.3 -8.0
Ademetionine -7.6 -7.4
N-Acetyl-D-Glucosamine -7.5 -6.0
Pentagalloylglucose -12.7 -8.9
Forsythiaside -11.7 -8.7
Root mean square de <italic toggle="yes">via</italic>tion (RMSD) graphs for the top hit compounds A: Lymecycline, B: Hexoprenaline, C: Pentagalloylglucose, D: Polydatin, E: Tricrocin, F: Setmelanotide, G: Forsythiaside.

The green graph shows fluctuations in the protein backbone from the initial reference point while the red shows the ligand fluctuations. The RMSD profile of the ligand is with respect to its initial fit to the protein binding pocket indicates that all ligands did not fluctuate beyond a 2-4 Å range.

 Interaction diagram of Lymecycline with S-RBD-ACE2 interface binding pocket.

(A) Interaction of lymecycline with residues in each trajectory frame. The depth of color indicating the higher the interaction with contact residues; (B) The protein-ligand contacts showing the binding interactions fraction; (C) Lymecycline interactions with the protein residues during MD simulation. Interactions shown are occurring more than 30% during the simulation time. A: chain A of the ACE2 binding domain, E: chain E of the S-glycoprotein receptor binding domain.

 Interaction diagram of Pentagalloylglucose with S-RBD-ACE2 interface binding pocket.

(A) Interaction of Pentagalloylglucose with residues in each trajectory frame. The depth of color indicating the higher the interaction with contact residues; (B) The protein-ligand contacts showing the bonding interactions fraction; (C) Pentagalloylglucose interaction with the protein residues during MD simulation. Interactions shown are occurring more than 30% during the simulation time.

 Interaction diagram of polydatin with S-RBD-ACE2 interface binding pocket.

(A) Interaction of polydatin with residues in each trajectory frame. The depth of color indicating the higher the interaction with contact residues; (B) The protein-ligand contacts showing the bonding interactions fraction; (C) Polydatin interaction with the protein residues during MD simulation. Interactions shown are occurring more than 30% during the simulation time.

Lymecycline shows an exceptional binding profile with key binding residues of the binding pocket as shown in Figure 4. Key binding residues of the S-RBD Lys417 and Gly496 form a H bonding interaction with the lymecycline, furthermore it exhibited water bridge interactions with Tyr 505 and Ser494. While at the interface lymecycline was also shown to form interactions with key binding residues of the ACE2 binding domain including a strong H bond with His34 and mixed interactions (ionic and hydrogen bonds) with residues Asp38 and Lys353. All significant interactions are represented in Figures 4 A and B, which highlight residues with the strongest ligand interactions that are stable over the entire simulation period. Figure 4 C depicts all significant interactions displayed by the ligand and interacting residues occurring for over 30% of the simulation period. Of significance Lys417 and Gly496 are bound to lymecycline over 60% of the simulation period.

MD simulation results for pentagalloylglucose in Figure 5 show significant interactions with key residues of the binding pocket. Key binding residues of the S-RBD: Lys417 and Gly496, form H bonds, and Lys417 was also shown to form a water bridge interaction with the ligand. Additionally, a stable hydrophobic interaction with residue Tyr505 was observed. Strong interactions with key residues of the ACE2 binding domain were also observed in the simulation period, notably H bonds and water bridges with residues Asp38 and Arg393. All significant interactions are represented in Figures 5A‐C. Of significance Lys417 interacts with pentagalloylglucose approximately 85% of the simulation period.

Polydatin exhibits several stable interactions throughout the 100 nanosecond simulation period as depicted in Figure 6. Polydatin binds with key residues of the S-RBD Lys417 and Tyr505. A mixed binding profile is observed including H bond interactions, water bridges and for Lys417 hydrophobic interactions. Polydatin was also shown to form interactions with key residues of the ACE2 binding domain including a strong hydrogen bond with His37 and mixed H bond and water bridge interaction with residue Asp30. All significant interactions are represented in Figure 6.

Binding free energy calculations MM/GBSA

Results for MM/GBSA binging free energy calculations are reported as a change in thermodynamic binding free energy (ΔGBind) of the ligand-protein complex in its most stable complexed configuration relative to the free energy of individual system binding partners and parameters in noncomplexed forms. The change in free energy was reported for the following compounds: lymecyclin, polydatin, setmelanotide, hexoprenaline, tricrocin, forsythiaside and pentagalloylglucose in Table 3. Results of MM/GBSA calculations complement the findings of the docking experiments and MD simulation. The ΔGBind is a composite of multiple components including the change of energy estimated from the formation of covalent bonds (ΔGCovalent), hydrogen bonds (ΔGHbond), lipophillic interactions (ΔGLipo), solvation energy (ΔGSolvation), and Van del Wal forces (ΔGvdW), each shedding light on distinct interaction dynamics between the ligands and the S-RBD-ACE2 binding pocket.

MM/GBSA binding free energy calculations.
Ligand bound to the S-glycoprotien ΔG bind (kcal/mol) ΔG bind Covalent (kcal/mol) ΔG bind vdW (kcal/mol) ΔG bind Lipo (kcal/mol) ΔG bind Hbond (kcal/mol) ΔG bind Solv (kcal/mol)
Lymecyclin -15.82 18.25 -26.84 -13.75 -4.64 -5.92
Polydatin -38.40 10.83 -34.17 -18.69 -4.15 35.30
Setmelanotide -38.68 10.80 -74.77 -11.13 -5.36 156.27
Hexoprenaline -53.75 9.11 -41.81 -21.99 -3.84 57.87
Tricrocin -60.19 13.91 -67.37 -29.92 -6.73 67.68
Forsythiaside -66.88 7.09 -50.38 -19.42 -5.79 55.34
Pentagalloylglucose -70.90 3.72 -60.50 -9.80 -9.03 64.44

In-silico pharmacokinetic calculations

The Absorption, Distribution, Metabolism, and Excretion–Toxicity (ADMET) profiles for the top seven hit drugs and nutraceuticals are listed in Table 4. The majority of the ligands are FDA approved drugs or nutraceuticals with known and reported physiochemical properties which were derived from the PubChem database, for unknown properties SwissADME and ADMETlab 2.0 were used to predict the parameters of interest. All ligands were found to have favorable ADMET profiles with no significant pharmacokinetic or toxicity parameters of concern.

ADMET profile for the top seven hit drugs and nutraceuticals. Verified and predicted values derived from PubChem database and using SwissADME and ADMETLab 2.0. PK: Pharmacokinetics.
Properties Parameters Lymecycline Hexoprenaline Setmelanotide Polydatin Tricrocin Pentagalloyl-glucose Forsythiaside
Physio-chemical MW (g/mol) 602.63 420.5 1117.3 390.38 814.82 940.68 624.59
Heavy atoms 43 30 78 28 57 67 44
H-bond acceptors 13 8 14 8 19 26 15
H-bond donors 9 8 15 6 11 15 9
Lipophilicity Log P o/w -1.56 1.53 -2.5 0.64 -1.09 0.22 -0.55
Water Solubility Log S (ESOL) -0.24 Very Soluble -2.55 Soluble 0.0286 Highly soluble -2.90 Soluble -3.65 Soluble -7.21 Poorly soluble -2.87 Soluble
PK GI absorption Low Low Low High Low Low Low
BBB permeability No No No No No No No
CYTP450 inhibitor No No No No No No No
Bioavailability score 0.11 0.55 0 0.55 0.17 0.17 0.17
Toxicity Hepatotoxicity nil nil nil nil nil nil nil
Carcinogenicity nil nil nil nil nil nil nil
Status Clinically approved Yes Yes Yes Yes
Experimental Yes Yes Yes
Discussion

Over the last two decades, different docking tools and programs have been developed that use different algorithms in which the conformation of the ligand is extensively evaluated in a binding pocket until an energy minimum is reached. Most programs treat the ligand as a flexible component and the receptor as rigid while others treat both interacting components (ligand and receptor) as flexible. 16 Such programs not only differ in the type of docking, but also in their ligand placement strategies. 24 In this study, we selected Schrödinger’s Maestro and Autodock vina in order to assess the docking accuracy and mode of binding. Autodock vina was used to perform rigid docking while maestro was used for induced fit (flexible) docking. Autodock uses the genetic algorithm while maestro uses systematic search techniques for ligand placement.

This study was a comprehensive in silico investigation of a key target of the SARS-CoV-2 virus; the surface S-glycoprotein or spike protein. The interaction between the S-glycoprotein and target ACE2 host receptor is essential to the virulent nature of the virus. Agents that can disrupt this binding interaction may potentially inhibit viral entry into the host cell and infection. Structures selected for this study were all solved by x-ray crystallography or EM with a minimum accepted resolution of 2.45 Angstrom. For each of the target structures, the selected binding pockets from Schrödinger’s Sitemap were verified by ensuring the presence of essential binding residues identified in previous studies ( Table 2). A detailed study of the viral host interface depicted in the 6M0J crystal structure revealed the key residues involved in strong charge assisted H bonds, ionic bonds, and strong H bonds, judged by the bond length, charge, and orientation ( Table 5). Binding to these residues is necessary to disrupt the natural interaction between the two proteins in favour of the hit ligand.

Key and allosteric binding residues of the binding pocket.
Protein name Key binding residues Allosteric binding residues Reference
SARS-CoV-2 S glycoprotein (spike protein) Lys417, Gly446, Leu455, Tyr449, Tyr453, Phe456, Phe486, Asn487, Tyr489, Gln493, Gly496, Gln498, Thr500, Asn501, Gly502, Tyr505 Gly488 Gly502 Asp427 Asp428 Lys986 Lys386 Leu387 Asp614 6 , 32 , 33
Angiotensin converting enzyme-2 (binding interface) Gln24, Thr27, Phe28, Asp30, Lys31, His34, Glu35, Glu37, Asp38, Tyr41, Gln42, Leu79, Met82, Tyr83, Asn330, Lys353, Gly354, Asp355, Arg357, Arg393 6 , 32

In our study, a comprehensive screening library of over 7000 compounds was compiled, comprised of both FDA and worldwide approved drugs and nutraceuticals in addition to all natural products with established in vivo activity (Zinc) 18 (Drugbank). 17 In order to ensure robust and reproducible results virtual screening was preformed using two different platforms: Glide 15 and Autodock Vina. 16 The thorough protocol employed within this study ensures that the hit ligands identified had verified binding profiles. Further molecular dynamic simulation studies were vital towards verifying and visualizing the nature of the binding interaction of the hit ligands within the binding interface. Hits, that were selected for MD simulation studies, were determined to be the most likely to disrupt the strongest interactions between the viral and host proteins ( Table 2). The current study benefited from a cross-docking protocol that utilized two different programs with two different algorithms to validate the results of the predicted docking poses of potential binders and increase the likelihood of getting satisfying results when proceeding with future laboratory and clinical testing. This was also further supported with a MD simulation for the best hits. MD simulation addresses important factors not included in the docking calculations such as binding site flexibility, solvent effects, and conformational changes, and thereby confirms the stability and the accuracy of the predicted docking conformations and increases the probability of being adopted in a real biological environment. Of interest a number of hit ligands identified in the study have been shown in the literature to express verified experimental antiviral activity, and this study sheds light on their plausible mechanisms of action. While the in-silico methodology employed in this study is comprehensive and supports reported evidence of potential antiviral activity for some hit ligands, future studies are required to validate activity and clinical efficacy.

MD simulation studies identified the following hit ligands: lymecycline, hexoprenaline, pentagalloylglucose, polydatin, tricrocin, setmelanotide and forsythiaside. All hits expressed a stable interaction profile as indicated by RMSD below 4 Å for both proteins and ligand position. It is important to highlight that all compounds were shortlisted from initial screening results based not only on their binding profile but also their suitability to be translated towards a clinical setting. Several drugs used in the management of COVID-19 have had detrimental effects owing to the adverse drug reaction profile of the employed therapeutic. The pathogenesis of COVID-19 culminates in several immune and cardiovascular manifestations ranging from hypercoagulability to kidney failure, as of such agents that are not appropriately selected may cause more harm than benefit within the overall scope of disease management. 25 Four hits were selected including lymecycline, pentagalloylglucose, polydatin, and hexoprenaline, which expressed very good RMSD profiles, indicating that the ligand remained bound in a stable manner within the binding pocket throughout the entirety of the simulation period. Other shortlisted ligands such as setmelanotide, and forsythiaside appear to have fluctuated with respect to their initial position relative to the protein backbone at some point within the simulation period although, the range of the fluctuation did not exceed beyond the range of 2-4 Å. The three final hits; lymecycline, pentagalloylglocose and polydatin, maintain strong bonds with residues within the binding pocket and in some cases vital binding residues throughout the entire simulation period. All seven hit candidates express favourable changes in binding free energy complementing the findings of MD simulation studies. Analysis of the pharmacokinetic and toxicity parameters of the hits revealed that all ligands have favourable and well tolerated ADMET profiles.

Lymecycline, a broad-spectrum second-generation tetracycline antibiotic commonly used in the management of acne, gynecological and respiratory tract infections, was shown to exhibit stable binding with key binding residues of both the spike and ACE2 RBD. Lymecycline maintained its interaction with its side chain throughout the simulation period. The stable charge assisted H bond with Lys 353 from ACE-2 and Gly 496 from spike was conserved during the dynamic simulation which suggests that these interactions are more energetically favoured over the initial H bond between the two mentioned residues. Other crucial interactions are shown with residues; Glu 37 and Asp 38 from ACE-2 and Tyr 505 from the S-RBD. These residues were bound via a H bond in the original protein-protein interaction. Lymecycline has been reported in previous studies to bind to additional viral targets in the SARS-CoV-2 virus, namely the main protease (M pro). 26 Like many members of its class it expresses anti-inflammatory properties, 27 this makes it a particularly attractive subject that can be further investigated for repurposing studies in the treatment of SARS-CoV-2.

Pentagalloylglucose is a polyphenolic compound that has been shown in in vitro and in vivo studies to have anti-viral effects against the hepatitis C virus. 28 A number of recent in vitro studies have shown a dose dependent effect in inhibiting viral spike association with the host ACE2 receptor. 29 Our study reveals the detailed nature of the binding interaction of pentagalloylglucose at the S-RBD-ACE2 binding interface. Key residues Lys417, Gly496 and Tyr505 of the viral spike protein and residues Asp38 and Arg393 of the ACE2 binding domain, form a stable binding interaction with pentagalloylglucose. Interference with viral-host binding at these key residues is very likely to be vital for the inhibition of viral engagement with the host ACE2 receptor and subsequent cell entry.

Polydatin, another polyphenolic compound, is a glycoside precursor of resveratrol. In vitro studies have shown its potential to inhibit viral spike protein binding with the ACE2 receptor. 30 The findings of this study corroborate our own where similar binding scores were reported. Furthermore, our studies identify strong interactions of the key binding residues Lys417 of the S-RBD and Asp30 and Glu37 of the ACE2 binding region with polydatin. It appears that interfering with the binding of the viral Lys417 residue is a key inhibitory pattern detected in a number of docking profiles supported by in vitro findings. 29 , 30

Hexoprenaline, a β2 adrenoceptor agonist, is mentioned as a drug of interest although it was not identified from the top three- hits that showed the most stable interactions during MD simulations. It is for the first time reported to exhibit a favourable binding profile with a number of key binding residues of the S-glycoprotein RBD as well as the ACE2 binding domain. Hexoprenaline was shown to bind key residues and to interrupt key interactions. One of its side-chain nitrogen atoms formed two charge assisted H bonds with the two initially bound residues Glu35 from ACE-2 and Gln493 from S-RBD. The other chain nitrogen formed a charge assisted H bond with Glu37 (see extended data for MD results of remaining shortlisted compounds). The stability of these critical bonds during dynamics was slightly lower than those noted for lymecycline during the simulation period. Yet, considering its role as a bronchodilator and its pharmacological profile it may be considered a good candidate for drug repurposing in the management of COVID-19 infection where there is a high incidence of respiratory distress. However, caution must be taken, considering its potential nonselective activity on β1 receptors which may result in unwanted cardiovascular effects. 31

In this study lymecycline, pentagalloylglucose, and polydantin were identified as potential inhibitors of the S-RBD-ACE2 binding interface. Hexoprenaline could be also considered as a promising hit, due to its favourable docking and dynamic profile and taking into account its relevance and suitability for clinical testing. Of the nutraceuticals, forsythiaside also appears promising in its ability to potentially disrupt key binding interactions at the viral-host interface and is a prime candidate for further in vitro and in vivo studies. From a clinical perspective, both lymecycline and hexoprenaline may be considered as possible candidates for translational and preliminarily clinical studies to assess their therapeutic potential in the management of COVID-19 infections.

 Conclusions

There have been a large number of docking studies published in the literature that have identified agents that may potentially be repurposed towards inhibiting SARS-CoV-2 targets. However, our study represents a unique and comprehensive approach to repurpose drugs that can bind to the viral S-glycoprotein-ACE2 binding interface using multiple platforms. Two different docking platforms were utilized and binding free energy calculations and molecular dynamic simulation studies were performed to identify a consistent binding pattern that appears to be common in the most effective agents that have the potential to inhibit the S-glycoprotein-ACE2 interaction. Seven drugs were identified as hits including, lymecycline, hexoprenaline, pentagalloylglucose, polydatin, tricrocin, setmelanotide and forsythiaside. The hits identified in this study were additionally shortlisted for their suitability to be translated to a clinical COVID-19 setting by understanding their toxicity profile and identifying agents with verified anti-inflammatory and anti-viral capacity. In our study lymecycline, and hexoprenaline are proposed as prime candidates for further translational, preclinical and clinical investigations for the treatment of COVID-19.

 Author contributions

D.H. designed the research project. D.H., M.G., A.A., and A.H. conducted the computational studies. D.H. and M.G. analyzed the results. S.M., H.A., M.A., helped draft the manuscript. All authors were involved in writing, editing and revision of the manuscript.

 Data availability Source data

Source data include the protein crystal structures which were retrieved from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) (RRID:SCR_012820). http://www.rcsb.org/#Category-welcome . The PDB accession code for the protein crystal structure of the S-glycoprotein bound to the ACE-2 receptor is 6M0J, and the pdb sturcture file can be accessed here: https://www.rcsb.org/structure/6m0j.

Additional source data include the ligand libraries which were retrieved from online databases: DrugBank database (RRID:SCR_002700) found here: http://www.drugbank.ca/. Annual account subscription and access to ligand libraries was kindly provided for the purpose of academic research. Freely available ligand libraries were downloaded from the open access Zinc database (RRID:SCR_006082) found here http://blaster.docking.org/zinc/. See Table sd1 below and/or in Table 1 in the main text for complete details. Ligand libraries used in the study.
Library Number of compounds Database Description Source: available for download from the following online databases
Natural products with experimentally verified in vivo activity 1,500 Zinc SDF files of approved natural products with in vivo efficacy http://blaster.docking.org/zinc/. (RRID:SCR_002700)
Food and Drug Administration (FDA) approved medications 1,100 DrugBank SDF files of FDA approved drugs http://www.drugbank.ca/. (RRID:SCR_002700)
FDA approved medications 1,614 Zinc SDF files of FDA approved drugs http://blaster.docking.org/zinc/. (RRID:SCR_002700)
Worldwide (not FDA) approved medications 3,440 DrugBank SDF files of worldwide approved drugs non-FDA http://www.drugbank.ca/. (RRID:SCR_002700)
Worldwide (not FDA) approved medications 4,288 Zinc SDF files of FDA approved drugs http://blaster.docking.org/zinc/. (RRID:SCR_002700)
Naturaceuticals 74 DrugBank SDF files of approved natraceutics http://www.drugbank.ca/. (RRID:SCR_002700)
Final Comprehensive library compiled composed of all compounds listed above, redundant structures were excluded 7,476 DrugBank and Zinc SDF files of all FDA and worldwide approved medications and natural products in addition to natural products with verified physiological activity http://www.drugbank.ca/. (RRID:SCR_002700) http://blaster.docking.org/zinc/. (RRID:SCR_002700)

Underlying data

Figshare: RAW DATA FILE: In silico drug repurposing using molecular docking and dynamics to target the protein interaction between the SARS-CoV -2 S-glycoprotein and the ACE2 receptor. https://doi.org/10.6084/m9.figshare.22257352.v5. 35

This project contains the following underlying data:

Simulation results: final trajectory frames of the hit compounds bound to the protein interface:

ligprep_DrugBannkApprovedNOMETAL28072021_maegz_1967.pdb

ligprep_DrugBannkApprovedNOMETAL28072021_maegz_2048.pdb

ligprep_DrugBannkApprovedNOMETAL28072021_maegz_135.pdb

ligprep_DrugBannkApprovedNOMETAL28072021_maegz_7.pdb

ligprep_DrugBannkApprovedNOMETAL28072021_maegz_654.pdb

ligprep_WorldappNOTFDAZinc_maegz_3777.pdb

ligprep_DrugBannkNaturaceuticalNOMETAL28072021_2_maegz_83.pdb

ligprep_DrugBannkNaturaceuticalNOMETAL28072021_2_maegz_5.pdb

ligprep_DrugBannkNaturaceuticalNOMETAL28072021_2_maegz_27.pdb

ligprep_NaturalINvivoZinc_NOMETAL_maegz_1403.pdb

ligprep_NaturalINvivoZinc_NOMETAL_maegz_1472.pdb

ligprep_WorldappNOTFDAZinc_maegz_3450.pdb

ligprep_WorldappNOTFDAZinc_maegz_40.pdb

Protein structure:

spikeACE2RBDinterface_protein.pdb

Ligand libraries derived from open-source databases:

FDAapproved medications.sdf

world-not-fdaApproved medication.sdf

NaturalcompoundsLibrary.sdf

Extended data

Extended Data: In silico drug repurposing using molecular docking and dynamics to target the protein interaction between the SARS-CoV -2 S-glycoprotein and the ACE2 receptor. https://doi.org/10.6084/m9.figshare.22414234.v1. 35

This project contains the following extended data:

Extended Data Insilico Drug repurposing SglycoproteinACE2.docx

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Acknowledgements

The authors acknowledge the support from the College of Clinical Pharmacy of Imam Abdulrahman Bin Faisal University, Saudi Arabia.

 References Chakraborty I Maity P : COVID-19 outbreak: Migration, effects on society, global environment and prevention. Sci. Total Environ. 2020;728:138882. 32335410 10.1016/j.scitotenv.2020.138882 PMC7175860 Chen Y Liu Q Guo D : Emerging coronaviruses: Genome structure, replication, and pathogenesis. J. Med. Virol. 2020;92(4):418–423. 31967327 10.1002/jmv.25681 PMC7167049 Huang Y Yang C Xu X-f : Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol. Sin. 2020;41(9):1141–1149. 32747721 10.1038/s41401-020-0485-4 PMC7396720 Wrapp D Wang N Corbett KS : Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263. 32075877 10.1126/science.abb2507 PMC7164637 Hoffmann M Kleine-Weber H Schroeder S : SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271–80.e8. 32142651 10.1016/j.cell.2020.02.052 PMC7102627 Wang Q Zhang Y Wu L : Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell. 2020;181(4):894–904.e9. 32275855 10.1016/j.cell.2020.03.045 PMC7144619 Walls AC Park YJ Tortorici MA : Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281–92.e6. 32155444 10.1016/j.cell.2020.02.058 PMC7102599 Choi JY Smith DM : SARS-CoV-2 Variants of Concern. Yonsei Med. J. 2021;62(11):961–968. 34672129 10.3349/ymj.2021.62.11.961 PMC8542474 Beigel JH Tomashek KM Dodd LE : Remdesivir for the Treatment of Covid-19 — Final Report. N. Engl. J. Med. 2020;383(19):1813–1826. 32445440 10.1056/NEJMoa2007764 PMC7262788 Roman YM Burela PA Pasupuleti V : Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. Clin. Infect. Dis. 2021. Eweas AF Alhossary AA Abdel-Moneim AS : Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2. Front. Microbiol. 2021;11. 33746908 10.3389/fmicb.2020.592908 PMC7976659 Das NC Chakraborty P Bayry J : In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike Protein. Front. Immunol. 2022;12. 35082779 10.3389/fimmu.2021.782506 PMC8784557 Touret F Gilles M Barral K : In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci. Rep. 2020;10(1):13093. 32753646 10.1038/s41598-020-70143-6 PMC7403393 Dodds MG Krishna R Goncalves A : Model-informed drug repurposing: Viral kinetic modelling to prioritize rational drug combinations for COVID-19. Br. J. Clin. Pharmacol. 2021;87(9):3439–3450. 32693436 10.1111/bcp.14486 PMC8451752 Friesner RA Murphy RB Repasky MP : Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 2006;49(21):6177–6196. 17034125 10.1021/jm051256o Trott O Olson AJ : AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010;31(2):455–461. 19499576 10.1002/jcc.21334 Wishart DS Feunang YD Guo AC : DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–D1082. 29126136 10.1093/nar/gkx1037 PMC5753335 Irwin JJ Sterling T Mysinger MM : ZINC: A Free Tool to Discover Chemistry for Biology. J. Chem. Inf. Model. 2012;52(7):1757–1768. 22587354 10.1021/ci3001277 PMC3402020 Kumar P Parveen Raj N Kumar M : Natural products from Streptomyces spp. as potential inhibitors of the major factors (holoRdRp and nsp13) for SARS-CoV-2 replication: an in silico approach. Arch. Microbiol. 2024;206(2):88. 38305873 10.1007/s00203-023-03820-5 Wang E Sun H Wang J : End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design. Chem. Rev. 2019;119(16):9478–9508. 31244000 10.1021/acs.chemrev.9b00055 Kim S Chen J Cheng T : PubChem 2023 update. Nucleic Acids Res. 2022;51(D1):D1373–D1380. 10.1093/nar/gkac956 Daina A Michielin O Zoete V : SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017;7(1):42717. 28256516 10.1038/srep42717 PMC5335600 Xiong G Wu Z Yi J : ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 2021;49(W1):W5–w14. 33893803 10.1093/nar/gkab255 PMC8262709 Pagadala NS Syed K Tuszynski J : Software for molecular docking: a review. Biophys. Rev. 2017;9(2):91–102. 28510083 10.1007/s12551-016-0247-1 PMC5425816 Kelly M O'Connor R Townsend L : Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin. Br. J. Clin. Pharmacol. 2021;87(3):1150–1154. 32687645 10.1111/bcp.14482 Wu C Liu Y Yang Y : Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm. Sin. B. 2020;10(5):766–788. 32292689 10.1016/j.apsb.2020.02.008 PMC7102550 Pradhan S Madke B Kabra P : Anti-inflammatory and Immunomodulatory Effects of Antibiotics and Their Use in Dermatology. Indian J. Dermatol. 2016;61(5):469–481. 27688434 10.4103/0019-5154.190105 Bernardi M Ghaani MR Bayazeid O : Phenylethanoid glycosides as a possible COVID-19 protease inhibitor: a virtual screening approach. J. Mol. Model. 2021;27(11):341. 34731296 10.1007/s00894-021-04963-2 PMC8565174 Chen RH Yang LJ Hamdoun S : 1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection. Front. Pharmacol. 2021;12:12. 10.3389/fphar.2021.634176 Perrella F Coppola F Petrone A : Interference of Polydatin/Resveratrol in the ACE2:Spike Recognition during COVID-19 Infection. A Focus on Their Potential Mechanism of Action through Computational and Biochemical Assays. Biomolecules. 2021;11(7):1048. 34356672 10.3390/biom11071048 PMC8301781 Pinder RM Brogden RN Speight TM : Hexoprenaline: a review of its pharmacological properties and therapeutic efficacy with particular reference to asthma. Drugs. 1977;14(1):1–28. 10.2165/00003495-197714010-00001 Lan J Ge J Yu J : Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215–220. 32225176 10.1038/s41586-020-2180-5 Verkhivker GM : Molecular Simulations and Network Modeling Reveal an Allosteric Signaling in the SARS-CoV-2 Spike Proteins. J. Proteome Res. 2020;19(11):4587–4608. 33006900 10.1021/acs.jproteome.0c00654 PMC7640983 Hussein D Mansour MS Matrafi A Al : Underlying data: In silico drug repurposing using molecular docking and dynamics to target the protein interaction between the SARS-CoV -2 S-glycoprotein and the ACE2 receptor.Dataset. figshare. 2023. 10.6084/m9.figshare.22257352.v5 Hussein D : Extended Data: In silico drug repurposing using molecular docking and dynamics to target the protein interaction between the SARS-CoV -2 S-glycoprotein and the ACE2 receptor.Dataset. figshare. 2023. 10.6084/m9.figshare.22414234.v1 10.5256/f1000research.169234.r307418 Reviewer response for version 2 Munikumar Dr Manne 1 Referee https://orcid.org/0000-0003-1838-122X ICMR-National Institute of Nutrition, Hyderabad, Telangana,, India

Competing interests: No competing interests were disclosed.

 28 10 2024 Copyright: © 2024 Munikumar DM 2024 This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. recommendation approve

Dear Author,

Your revised manuscript, entitled "In Silico Drug Repurposing Using Molecular Docking and Dynamics to Target the Protein Interaction Between the SARS-CoV-2 S-Glycoprotein and the ACE2 Receptor," may be considered for indexing in the esteemed journal.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

Reviewer Expertise:

Molecular Docking, Bioinformatics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

 10.5256/f1000research.169234.r317619 Reviewer response for version 2 Kumar Vipul 1 Referee https://orcid.org/0000-0001-7578-7467 Tiwari Vikas 1 Co-referee Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA

Competing interests: No competing interests were disclosed.

 10 9 2024 Copyright: © 2024 Kumar V and Tiwari V 2024 This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. recommendation approve-with-reservations

Authors have conducted an extensive screening and modeling study. However, I suggest addressing the points below to enhance the paper:

1. The binding sites were enclosed in a grid box of 20 ų without constraints using default parameters." (The grid box size of 20 ų seems very small and needs verification.)

2. The final complex configuration from compiled trajectories of a 100 ns MD simulation was used to calculate the MMGBSA free energy. (Consider calculating across the trajectory or using cluster representatives.)

3. Upon designing the study and to this date there are no known solved crystal structures for the SARS-Cov-2 RBD and ACE2 complex bound to a ligand within the interacting binding pocket, as of such for the purpose of validation two different docking platforms were employed in the initial docking investigations to screen and shortlist suitable candidates targeting our region of interest in the viral-host interface. (Improve the sentence)

4. The Gly496 from the spike protein" (Glycine does not have a side chain. Refer to it as the Gly496 backbone)

5. "RMSD analysis revealed a stable binding profile for the top 7 ligands as shown." (RMSD, not RMDS.)

6. The side effects of the top hits should be discussed.

7. All hits expressed a stable interaction profile as indicated by RMSD below 4 Å for both proteins and ligand position." (Not correct as per the Figure 3)

8. Can these compounds bind with a similar score to individual ACE2 or spike proteins alone?

9. Are there other docking studies targeting ACE2-spike interactions? If so, the top hits from those studies could be used for comparison."

Is the work clearly and accurately presented and does it cite the current literature?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

Reviewer Expertise:

Molecular Modelling and Computational Drug Discovery.

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

 10.5256/f1000research.144356.r260767 Reviewer response for version 1 Munikumar Dr Manne 1 Referee https://orcid.org/0000-0003-1838-122X ICMR-National Institute of Nutrition, Hyderabad, Telangana,, India

Competing interests: No competing interests were disclosed.

 20 5 2024 Copyright: © 2024 Munikumar DM 2024 This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. recommendation approve-with-reservations

Dear Authors,

The manuscript entitled “In silico drug repurposing using molecular docking and dynamics to target the protein interaction between the SARS-CoV-2 S-glycoprotein and the ACE2 receptor.” thoroughly assessed. The manuscript demonstrates a rigorous methodology, employing two different computational platforms for virtual screening, molecular docking, and molecular dynamics simulations. This comprehensive approach enhances the reliability and robustness of the findings. The study addresses an important and timely topic by focusing on the protein interaction between the SARS-CoV-2 S-glycoprotein and the ACE2 receptor, which is crucial for viral entry and infection. The potential for drug repurposing strategies to combat COVID-19 is underscored, highlighting the significance of the research. The manuscript successfully identifies several potential hit compounds with stable interactions at the viral-host interface. The selection of lymecycline, pentagalloylglucose, polydatin, and hexoprenaline for further investigation demonstrates promising results and provides a basis for future experimental studies. The study provides valuable insights into the binding mechanisms of the identified hit compounds, elucidating their interactions with key viral and host residues. This deepens understanding of the molecular basis of SARS-CoV-2 infection and potential therapeutic interventions. The conclusion offers practical implications by suggesting lymecycline and hexoprenaline as candidates for preliminary clinical studies. This highlights the translational potential of the findings and their relevance for the development of COVID-19 therapeutics. Following comments has to be addressed.

While the computational approach is thorough, experimental validation of the findings is lacking. Incorporating in vitro or in vivo studies to confirm the efficacy of the identified compounds would strengthen the manuscript and provide more robust evidence for their potential as therapeutics.

The manuscript could benefit from a more comprehensive discussion of the limitations and assumptions of the computational methods employed. Addressing factors such as binding site flexibility, solvent effects, and conformational changes could enhance the interpretation of the results and their relevance to real-world scenarios.

The study focuses on a specific set of compounds and interactions, which may limit its generalizability to other drug candidates or viral strains. Discussing the broader implications of the findings and potential applicability to related viruses or drug targets would enrich the manuscript.

It would be beneficial for the authors to provide information on the availability of the datasets, software codes, and molecular structures used in the study. Enhancing data accessibility would promote transparency and reproducibility in computational drug discovery research.

While the selected compounds show promise in silico, their clinical feasibility and safety profiles need to be thoroughly evaluated. Discussion of potential side effects, pharmacokinetic properties, and drug interactions would provide a more comprehensive assessment of their suitability for clinical trials.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

Reviewer Expertise:

Molecular Docking, Bioinformatics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

hussein dania Imam Abdulrahman bin Faisal University, Saudi Arabia

Competing interests: No competing interests were disclosed.

 15 7 2024

We thank the esteemed reviewer for his valued input and comments. We have addressed and responded to each comment accordingly:

 

While the computational approach is thorough, experimental validation of the findings is lacking. Incorporating in vitro or in vivo studies to confirm the efficacy of the identified compounds would strengthen the manuscript and provide more robust evidence for their potential as therapeutics.

We thank the reviewer for this valuable comment. The current research involves in silico drug repurposing for COVID-19 through identifying potential ligands that bind at the protein-protein interface and inhibits the interaction of SARS-CoV -2 S-glycoprotein and the ACE2 receptor. This represents the first step of a translational research project to shortlist potential binders to be followed by in vitro and in vivo studies and finally clinical testing and repositioning. A further level of validation has been incorporated by considering historical evidence of biological activity of experimental ligands known to disrupt the viral host (S-RBD) and receptor (ACE-2) interaction. We have been able to show that experimental agents with biological activity also express binding affinity using our employed docking protocol.

 

The manuscript could benefit from a more comprehensive discussion of the limitations and assumptions of the computational methods employed. Addressing factors such as binding site flexibility, solvent effects, and conformational changes could enhance the interpretation of the results and their relevance to real-world scenarios.

We thank the reviewer for this observation and have included the following paragraph to the discussion section:

The current study benefited from a cross-docking protocol that utilized two different programs with two different algorithms to validate the results of the predicted docking poses of potential binders and increase the likelihood of getting satisfying results when proceeding with future laboratory and clinical testing. This was also further supported with a MD simulation for the best hits. MD simulation addresses important factors not included in the docking calculations such as binding site flexibility, solvent effects, and conformational changes, and thereby confirms the stability and the accuracy of the predicted docking conformations and increases the probability of being adopted in a real biological environment. Of interest a number of hit ligands identified in the study have been shown in the literature to express verified experimental antiviral activity, and this study sheds light on their plausible mechanisms of action. While the in-silico methodology employed in this study is comprehensive and supports reported evidence of potential antiviral activity for some hit ligands, future studies are required to validate activity and clinical efficacy.

 

The study focuses on a specific set of compounds and interactions, which may limit its generalizability to other drug candidates or viral strains. Discussing the broader implications of the findings and potential applicability to related viruses or drug targets would enrich the manuscript.

Thank you for this important observation. While drug repurposing is a well-known drug discovery strategy that gained high attention and applicability during the past few decades, this research represents a rational drug discovery project that focuses on a specific protein-protein interaction for the challenging new virus. COVID-19, in an attempt to overcome potential future outbreaks and devastating pandemic. The generalizability of this approach is highlighted; specifically, the benefits of utilizing in silico platforms towards a repurposing strategy have been highlighted in the text. It is important to note that our hit compounds were selected based on a detailed analysis of their pharmacological profiles and suitability for translation towards a clinical setting. While a number of similar studies report compounds based mainly on favorable binding scores we carefully filtered through the hit compounds and determined those with complementary pharmacological and safety profiles. It is this comprehensive approach we hope will improve the clinical translatability of our findings.

 

It would be beneficial for the authors to provide information on the availability of the datasets, software codes, and molecular structures used in the study. Enhancing data accessibility would promote transparency and reproducibility in computational drug discovery research.

Thank you for this comment, we have now included the following section to the materials and methods:

The crystal structures analysed during the current study are available in the PDB database, [PDB ID: 6M0J]”. The molecular structures of the compound’s datasets used were obtained from DrugBank database ( https://go.drugbank.com/drugs )

 and Zinc database ( https://zinc.docking.org/substances/subsets/fda/ )

 

While the selected compounds show promise in silico, their clinical feasibility and safety profiles need to be thoroughly evaluated. Discussion of potential side effects, pharmacokinetic properties, and drug interactions would provide a more comprehensive assessment of their suitability for clinical trials.

We thank the reviewer for this helpful comment. We have accordingly included additional data on the pharmacokinetic profiles for the top hit ligands. It is important to note that the current research utilized ligands from worldwide approved and USFDA approved drugs and nutraceuticals, all of which are clinically used medications or natural compounds with known drug-drug interactions, pharmacokinetic, and toxicity profiles. We have in the discussion highlighted the clinical translatability and significance of repurposing drugs such as Lymecycline and Hexoprenaline in the clinical setting COVID-19 and their plausible applicability. The clinical feasibility and limitations of select hit compounds are discussed in light known clinical and experimental findings. Our repurposing approach in this study aims to gives the work more translatability towards a clinical setting.

10.5256/f1000research.144356.r244892 Reviewer response for version 1 Kumar Prateek 1 Referee https://orcid.org/0000-0003-2321-221X University of Allahabad, Prayagraj, India

Competing interests: No competing interests were disclosed.

 1 3 2024 Copyright: © 2024 Kumar P 2024 This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. recommendation approve-with-reservations

Review Report:

The title of manuscript is interesting but it requires major revisions before getting  approved. Authors are requested to incorporate following suggestions:

Major revisions:

1. Validation of docking results is missing, please include the validation of molecular docking.

2. Perform ADMET analysis to check the drug abilities/potential of screened compounds.

3. Perform binding free energy calculations MM/GBSA.

Minor revisions:

4. Improve the conclusion part in Abstract as well as the final conclusion. It should be more conclusive not broad.

5. Manuscript require thorough checking of Grammer and typo errors.

Is the work clearly and accurately presented and does it cite the current literature?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Not applicable

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Is the study design appropriate and is the work technically sound?

Partly

Are the conclusions drawn adequately supported by the results?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

Reviewer Expertise:

Bioinformatics, Molecular Biology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

References : Natural products from Streptomyces spp. as potential inhibitors of the major factors (holoRdRp and nsp13) for SARS-CoV-2 replication: an in silico approach. Arch Microbiol .2024;206(2) : 10.1007/s00203-023-03820-5 88 38305873 10.1007/s00203-023-03820-5 hussein dania Imam Abdulrahman bin Faisal University, Saudi Arabia

Competing interests: No competing interests were disclosed.

 15 7 2024

We thank the esteemed reviewer for his valued input and comments. We have addressed and responded to each comment accordingly:

Major revisions:

1. Validation of docking results is missing, please include the validation of molecular docking.

We thank the esteemed reviewer for their valuable comments and helpful suggestions. We have added a additional paragraph regarding the protocol validation. Due to the absence of any verified crystal structure of ligands bound to the SARS-Cov-2 receptor binding domain and ACE2 interface we utilized the Site Score tool on Maestro to identify and calculate the region with the highest druggability that encompasses the interactions of interest. The key interactions between the viral host and receptor have been determine and verified and we were keen to identify agents that could disrupt such interactions. Using SiteScore the binding pocket with thus determined and for validation we employed 2 different docking platforms: Glide and AutoDoc Vina. For an additional level of validation supported by experimental evidence ligands with verified activity against the S-glycoprotein-ACE2 interaction were docked using Glide. Biological activity was assessed and IC50 values determined in previous studies, this was compared to the determined binding affinities represented by the docking scores attained using the extra precision docking protocol. The findings provided another tier of validation highlighting a complementary association between the calculated binding affinities and experimental activity of our designated control ligands, this data is available in the Extended Data file.

2. Perform ADMET analysis to check the drug abilities/potential of screened compounds.

Thank you for this suggestion ADMET values were derived for the top seven ligands are presented as a table in the manuscript.

3. Perform binding free energy calculations MM/GBSA.

Thank you for this valuable suggestion, we have accordingly preformed free energy calculations and added this data to the manuscript.

Minor revisions:

4. Improve the conclusion part in Abstract as well as the final conclusion. It should be more conclusive not broad.

The abstract conclusion part was rewritten as follows:

Our study represents a rational drug discovery approach that utilizes a unique and comprehensive approach to identify agents that can bind to the S-glycoprotein-ACE2 interface using multiple computational platforms. Seven hits were identified: lymecycline, hexoprenaline,  pentagalloylglucose, polydatin, tricrocin, setmelanotide and forsythiaside. Among the hit compounds shortlisted in this study, both lymecycline and hexoprenaline were considered to be two significant drug hits in terms of their applicability in COVID-19 clinical settings and therefore are considered primary candidates for translational and clinical studies to assess their therapeutic potential in the management of COVID-19 infections.

The conclusion part was rewritten as follows:

There have been a large number of docking studies published in the literature that have identified agents that may potentially be repurposed towards inhibiting SARS-CoV-2 targets. However, our study represents a unique and comprehensive approach to repurpose drugs that can bind to the viral S-glycoprotein-ACE2 binding interface using multiple platforms. Two different docking platforms were utilized and binding free energy calculations and molecular dynamic simulation studies were performed to identify a consistent binding pattern that appears to be common in the most effective agents that have the potential to inhibit the S-glycoprotein-ACE2 interaction. Seven drugs were identified as hits including, lymecycline, hexoprenaline, pentagalloylglucose, polydatin, tricrocin, setmelanotide and forsythiaside. The hits identified in this study were additionally shortlisted for their suitability to be translated to a clinical COVID-19 setting by understanding their toxicity profile and identifying agents with verified anti-inflammatory and anti-viral capacity. In our study lymecycline, and hexoprenaline are proposed as prime candidates for further translational, preclinical and clinical investigations for the treatment of COVID-19.

5. Manuscript require thorough checking of Grammar and typo errors.

Thank you for this helpful observation, we have accordingly revised the manuscript for mistakes.